Scarica l'app Stockscreener
3.06
1.32%
0.04
Dopo l'orario di chiusura:
3.02
-0.04
-1.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$3.02
Aprire:
$3.08
Volume 24 ore:
3.46M
Relative Volume:
0.86
Capitalizzazione di mercato:
$594.73M
Reddito:
$41,000
Utile/perdita netta:
$-88.09M
Rapporto P/E:
-3.0136
EPS:
-1.0154
Flusso di cassa netto:
$-67.55M
1 W Prestazione:
+11.68%
1M Prestazione:
-8.38%
6M Prestazione:
-18.40%
1 anno Prestazione:
-43.65%
Intervallo 1D:
$3.00
$3.15
Intervallo di 1 settimana:
$2.56
$3.15
Portata 52W:
$2.56
$7.73
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.06 | 586.95M | 41,000 | -88.09M | -67.55M | -1.0154 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Aggiornamento | Goldman | Sell → Neutral |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
MSN Money - MSN
Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com
Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan
Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan
Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan
Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan
Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan
Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan
[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan
Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan
RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan
Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan
Dilution fears return: Why ALT stock is getting hit again - MSN
ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan
ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView
Altimmune a new buy at Truist on pemvidutide promise - MSN
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union
Altimmune catalysts: 2026 data readouts and financing risks - MSN
Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter
Altimmune closes $225M financing for MASH drug trial - Investing.com UK
Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals
Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz
Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail
Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan
Altimmune prices $75M direct offering - MSN
Altimmune shares slide after $75 million registered direct offering - MSN
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):